Open AccessMonitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
Author(s) -
Ю. Ю. Киселёв,
А. В. Матвеев,
К. Б. Мирзаев,
Д. А. Сычёв
Publication year - 2020
Publication title -
kačestvennaâ kliničeskaâ praktika
Language(s) - English
Resource type - Journals
eISSN - 2618-8473
pISSN - 2588-0519
DOI - 10.37489/2588-0519-2020-s4-115-119
Subject(s) - pharmacovigilance , medicine , favipiravir , adverse effect , intensive care medicine , alertness , medical emergency , pharmacology , covid-19 , disease , infectious disease (medical specialty)
Global experience with the clinical use of favipiravir is very limited. Its safety is for further study. Prevention of teratogenic effects (mandatory pregnancy test before starting therapy, compliance with effective contraception by both women and men), control of the level of uric acid, transaminases and ECG are of fundamental importance. Alertness is needed for new, insufficiently documented or previously unreported adverse events such as motor disturbances and falls. Patients should be fully informed about all the risks of therapy before starting it. Special attention is required to timely fill out the approved forms of notifications on the development of HP and report them in time according to the Order of the Federal Service for Surveillance in Healthcare of February 15, 2017 No. 1071 «On approval of the Procedure for the implementation of pharmacovigilance.»